Tag:
Jazz Pharmaceuticals
Latest Headlines
Latest Headlines
Jazz Pharma snaps up Eusa in $700M buyout deal
The Ireland-based drugmaker ($JAZZ) says it will shell out $650 million upfront and potentially $50 million more to scoop up Eusa Pharma and its drugs for cancer and critical care.
Jazz Pharmaceuticals announces another deal
Just months after completing a merger with Azur Pharma, Jazz has picked up specialty drugmaker Eusa Pharma for up to $700 million.
Jazz didn't notify FDA of 74 serious side-effect reports
The FDA has issued a stern warning to Jazz Pharmaceuticals ( $JAZZ ), saying the company failed to properly report serious side effects of its drugs. Jazz also failed to submit reports on 74 serious
Jazz Pharma basks in praise as it adds CNS drugs in Azur acquisition
Occasionally cited as a potential takeover target, Jazz Pharmaceuticals ( $JAZZ ) is in the news this morning with a takeover of its own. The biotech says it has struck an all-stock deal to acquire
Jazz shares hit sour note as FDA rejects fibromyalgia drug
The FDA has handed Jazz Pharmaceuticals a setback, spurning its application for a new therapy to treat fibromyalgia and sending the developer back to the drawing board for fresh data on JZP-6 that
Jazz fibromyalgia drug nixed by FDA panel
An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the
FDA panel nixes Jazz drug for fibromyalgia
An FDA advisory panel meeting Friday poured cold water on Jazz Pharmaceuticals' bid to market JZP-6 as a treatment for fibromyalgia as the drug contains a form of gamma hydroxybutyrate (GHB), the
Zombie biotechs become life of the Wall Street party
A year ago the smart money was betting that the biotech industry in the U.S. was headed straight for a cliff . Analysts warned of " zombie " biotechs as shares of 70 biotech companies were trading for
Jazz puts three programs on hold
Just days after seeing its badly battered stock price pick up on positive late-stage data from its fibromyalgia program, Jazz Pharmaceuticals told Reuters it's putting three of its programs on hold
Jazz shares hit high note on fibromylagia data
Shares of Jazz Pharmaceuticals shot up 32 percent this morning after the developer detailed positive Phase III data for a new drug--JZP-6--that treats the pain and main symptoms linked with
